Andy Studna
Verified
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Andy Studna
Applied Clinical Trials — FDA Finalizes Three Guidances to Broaden Cancer Clinical Trial Eligibility
New documents targeting performance status, washout periods, and laboratory value thresholds aim to close the gap between patients willing to participate in oncology trials and those who actually enroll.
Addressing Regional Variation in Clinical Trial Risks
Sylviane de Viron, data and knowledge manager at CluePoints Regional risk variation by the numbers Analysis included 585 trials, 46 sponsors and CROs, and more than 56,000 sites across seven global regions Region was the primary driver of KRI variation, while study phase, therapeutic area, and study size showed minimal impact Four KRIs showed the widest regional spread: off-schedule visit rate, protocol deviation rate, screen failure rate, and serious AE rate North America demonstrated a 29%...
ACT Brief: Targeted Trial Growth, Site Startup Strains, and Leadership Shake-Up at FDA
News|Podcasts|December 4, 2025 In today’s ACT Brief, we look at new insights on strategy-driven clinical development, fresh survey data revealing persistent site startup delays, and major leadership turnover inside FDA’s drug division. This is the Applied Clinical Trials Brief—your fast track to the latest insights in clinical research operations. In under three minutes, we’ll recap top stories, highlight expert perspectives, and keep you current on what’s moving the industry.
CNS and Autoimmune Trials: Growth and Operational Implications
In a recent video interview with Applied Clinical Trials, Heidi Chen, Associate Director of Research & Commercial Services at Citeline, discussed findings from the company’s 2025 Annual Clinical Trials Roundup. She outlined how personalized and biomarker-based therapies are creating opportunities and challenges for trial design, especially in rare disease populations, and highlighted the use of historical controls and real-world evidence to support targeted development.
Targeted and Strategy-Driven Clinical Development
In a recent video interview with Applied Clinical Trials, Heidi Chen, Associate Director of Research & Commercial Services at Citeline, discussed findings from the company’s 2025 Annual Clinical Trials Roundup. She outlined how personalized and biomarker-based therapies are creating opportunities and challenges for trial design, especially in rare disease populations, and highlighted the use of historical controls and real-world evidence to support targeted development.
Modernizing Recruitment with Data, HCP Networks, and Last Mile Support
In a recent video interview with Applied Clinical Trials, Matt Holms, vice president of sales at Citeline, discussed the persistent barriers slowing patient recruitment and how technology and data-driven strategies can help modernize clinical trial operations. He outlined factors such as site performance variability, investigator scarcity, and protocol complexity as key contributors to trial delays, emphasizing the need for more realistic protocol design informed by real-world data.
Rethinking Site Selection and Oversight Amid Complex Protocols
In a recent video interview with Applied Clinical Trials, Matt Holms, vice president of sales at Citeline, discussed the persistent barriers slowing patient recruitment and how technology and data-driven strategies can help modernize clinical trial operations. He outlined factors such as site performance variability, investigator scarcity, and protocol complexity as key contributors to trial delays, emphasizing the need for more realistic protocol design informed by real-world data.
Scaling Recruitment Across Therapeutic Areas and Regions
In a recent video interview with Applied Clinical Trials, Matt Holms, vice president of sales at Citeline, discussed the persistent barriers slowing patient recruitment and how technology and data-driven strategies can help modernize clinical trial operations. He outlined factors such as site performance variability, investigator scarcity, and protocol complexity as key contributors to trial delays, emphasizing the need for more realistic protocol design informed by real-world data.
ACT Brief: Data Strategy, AI Integration, and Rare Disease Milestones Drive Clinical Innovation
News|Podcasts|November 6, 2025 In today’s ACT Brief, we highlight new insights on recruitment bottlenecks from Citeline’s Matt Holms, UCB’s first-in-class approval for TK2 deficiency, and why strong data foundations are key to realizing AI’s full potential in pharma. This is the Applied Clinical Trials Brief—your fast track to the latest insights in clinical research operations.
Inside the Recruitment Bottlenecks Driving Trial Delays
In a recent video interview with Applied Clinical Trials, Matt Holms, vice president of sales at Citeline, discussed the persistent barriers slowing patient recruitment and how technology and data-driven strategies can help modernize clinical trial operations. He outlined factors such as site performance variability, investigator scarcity, and protocol complexity as key contributors to trial delays, emphasizing the need for more realistic protocol design informed by real-world data.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
Key takeaways Placebo-controlled trials now required for low-risk groups: FDA will require placebo-controlled trials for COVID-19 vaccines in low-risk populations before granting full approval—adding complexity to trial design, ethics reviews, and recruitment. New focus on clinical outcomes & longer follow-up: Trials must now measure symptomatic COVID-19 as the primary endpoint, include participants with prior infections, and follow them for at least six months.
FDA Approves Johnson & Johnson’s VARIPULSE Pulsed Field Ablation Platform for AFib
Johnson & Johnson MedTech announced that the U.S. Food and Drug Administration (FDA) has approved its VARIPULSE Platform for treating drug-refractory paroxysmal atrial fibrillation (AFib). This approval is based on findings from the admIRE clinical trial, which reported that 100% of patients achieved acute procedural success, with 98% achieving first-pass isolation per vein.
Prilenia Announces Plans to Initiate Global Phase III Study of Novel ALS Treatment
Prilenia Therapeutics B.V. has announced it will present clinical data supporting a future Phase III study of the investigational therapy pridopidine for amyotrophic lateral sclerosis (ALS). Prilenia, a clinical stage biotechnology company that develops treatments for neurodegenerative diseases and neurodevelopmental disorders, plans to present the data during the 14th Annual California ALS Research Summit in Los Angeles.
Antibiotic for Uncomplicated Urinary Tract Infections Granted FDA Priority Review
Utility Therapeutics, a UK-based biotechnology company, announced that the FDA has granted priority review to its new drug application (NDA) for pivmecillinam, a European-approved treatment of uncomplicated urinary tract infections (UTIs).1 According to Medscape, UTIs occur far more frequently in women, with 20% having at least one in their lifetime. It is responsible for at least 8 million visits to healthcare facilities in the US per year.
Generative Artificial Intelligence Could Transform Healthcare if Challenges Are Addressed
Published on: Critical factors need to be addressed for pharma stakeholders to realize the full potential of generative artificial intelligence. Over the past few years, the world of generative artificial intelligence (genAI) took large steps forward with the introduction of tools such as the popular ChatGPT, which have elicited excitement across all industries; however, concerns remain.
CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel for Severe Sickle Cell Disease
CRISPR Therapeutics has announced the completion of the FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of sickle cell disease (SCD) in patients aged 12 years and older with recurrent vaso-occlusive crises (VOCs).
Survey: Technology and drug pricing clarity key to industry recovery
Proposed moves aimed at gaining ‘most-favored nation’ drug pricing so that Medicare pays the same drug prices as other developed countries would face significant barriers to implementation, according to results of a survey released this week by Model N, Inc., a technology provider for many large pharma companies.
Schreiner MediPharm equips Cap-Lock security label with RFID technology
Schreiner MediPharm, a Germany-based provider of functional labels for the healthcare industry, has augmented its Cap-Lock tamper-evident specialty label with an RFID inlay. Cap-Lock label now equipped with RFID inlay. (Credit: Schreiner MediPharm) Developed to expand digitization initiatives at hospitals, the label-and-cap security concept for prefilled syringes now enables automated inventory and supply chain management, as well as digital first-opening indication.
Stevanato to expedite delivery of visual inspection systems to Catalent sites
Stevanato Group has expanded its collaboration with Catalent to include delivery of advanced visual inspection systems to help with potential Covid-19 pandemic programs, biologics and sterile injectable products. Under the expanded arrangement, Catalent has ordered Plus 400 LKD automatic and PWL semi-automatic visual inspection machines from Stevanato and will install the equipment at its sites in Bloomington, IN and Anagni, Italy. Plus 400 LKD inspection machine.
Catalent to acquire cell therapy manufacturing facility in Belgium
Catalent has signed an agreement with Bone Therapeutics to acquire its cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support SA, including all of its assets located in Gosselies, Belgium. The transaction is expected to close in November. The Skeletal Cell Therapy Support manufacturing facility in Gosselies, Belgium.
Trebor Rx to begin production of TPE respirator masks in Canada
Trebor Rx, a new venture in Canada, is launching PRO+ Dual Respirator masks, a patent-pending mask made of thermoplastic elastomer (TPE) that can provide more than 300 hours of usage and replace hundreds of disposable masks, according to the company. The PRO+ Dual Respirator masks (Image credit: CNW Group/Trebor Rx Corp.) The respirator body is 95 percent recyclable, washable and sterilizable.
Carrier Pods in combo with Sensitech provide new mobile cold storage option
New Carrier Pods monitored by Sensitech combine refrigeration technology and cargo monitoring capabilities to help address the challenges of Covid-19 vaccine distribution. Carrier and Sensitech both are part of Carrier Global Corp., a worldwide provider of building and cold chain options.
New alliance formed to serve biopharmaceutical and life sciences
Rapid Reshore & Development (RR&D), an alliance of three specialized firms working together to provide professional services for the life sciences and biopharmaceutical industries, has formed to address logistical challenges facing companies developing drugs, vaccines and medical devices. The three firms—Facility Logix, EwingCole and Biggins Lacy Shapiro & Co.—intend to maximize efficiency, minimize risk and facilitate speed-to-market.
TFF Pharmaceuticals expands its cGMP manufacturing capabilities
TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, has expanded its engagement with contract manufacturing organization (CMO) Experic, LLC to install its patented thin film freezing (TFF) processing line and associated capabilities at the CMO’s cGMP facility in Cranbury, NJ. Installation of the custom-designed equipment is expected to be completed in early Q2 2021.
West Pharma’s vial to IV bag admixture device cleared by FDA for drug transfer
West Pharmaceutical Services, Inc. has received FDA 510(k) clearance of its Vial2Bag Advanced 20mm Admixture Device, which enables reconstitution and transfer of a drug between a vial and an IV bag. The needle-free device is suited for immediate use and can optimize pharmacy cleanroom time, while assisting in standardizing admixture systems to maximize the efficiency of point-of-care nursing and can be an effective solution for meeting USP <797> compounding requirements, according to the company.
Envirotainer adds four new RAP e2 stations in the US
Envirotainer, a global provider of temperature-controlled air freight equipment and technology for pharmaceuticals, is increasing its RAP e2 network capacity in the US by 57 percent. The four new RAP e2 stations in New York, Miami, Philadelphia and Seattle will increase the capacity to securely ship both Covid-19 vaccines as well as all other medicines that require high-quality temperature-controlled packaging solutions. Secure cold chain services for the pharmaceutical supply chain.
CSafe expands further into Latin America
CSafe Global, provider of temperature-controlled containers for the transport of pharmaceuticals, has opened a new hub operation in Mexico City, the second largest pharmaceutical market in Latin America after Brazil. Mexico City (Image courtesy of CSafe Global) “We are thrilled to add our second facility in Latin America in 2020,” said Tom Weir, chief operating officer at CSafe.
New business options aim to ease clinical budget headaches
Strategikon Pharma is expanding its Clinical Maestro business operations platform for biopharmaceutical participants with two new offerings, a full-service model and an operator model. The company provides a Software as a Service (SaaS) product license for clinical trial RFP planning and budgeting, which includes implementation and training.
BioSpecifics to be acquired by Endo Pharmaceuticals
Endo International plc will acquire BioSpecifics Technologies Corp. in an all cash transaction totaling an estimated $658 million in equity value. The transaction was unanimously approved by the boards of both companies and is expected to close during the current quarter. Under the terms of the agreement, Endo, through a wholly owned subsidiary, will commence an all-cash tender offer for all outstanding shares of BioSpecifics common stock at a price of $88.50 per share.
Reflect Scientific awarded patent for low temperature bulk shipping system
Reflect Scientific, Inc. has been awarded a patent for a cryogenic modular shipping unit that can uniformly maintain its payload at temperatures as low as -90°C, making it suited for cold chain management of biologics including Covid-19 vaccines. The cryogenic system provides a capability of short or long duration bulk shipping and may also be used for long-term storage. Low-temperature shipping system for high-value vaccines and biologicals.
LaunchWorks makes FDA list of approved viral transport media vendors
LaunchWorks, a contract development and manufacturing organization (CDMO) serving the life sciences market, has been approved to manufacture and distribute viral transport media (VTM), in accordance with Section IV.B of the FDA’s Covid-19 transport media policy.
HFAP joins ACHC in move that streamlines accreditation and certification services
The Accreditation Commission for Health Care (ACHC) and Healthcare Facilities Accreditation Program (HFAP) are joining to form a single company providing accreditation and certification services to providers. Under the October 19 merger agreement between ACHC and Accreditation Association for Hospitals/Health Systems (AAHHS)—HFAP’s parent company—HFAP will operate as a brand within ACHC.
AGC Biologics shifts leadership structure at US and Copenhagen sites
AGC Biologics, a biopharmaceutical contract development and manufacturing organization (CDMO), has announced leadership changes atits US and Copenhagen, Denmark operations. The changes became effectiveOctober 15. Jeffrey D. Mowery, formerly general manager of the Copenhagen site, joins the global executive team at the company’s headquarters in Seattle as senior vice president of US operations.
SkyBitz and Coretex enter strategic alliance to integrate reefer and trailer tracking
IoT telematics company SkyBitz and fleet logistics technology provider Coretex are partnering to provide pharmaceutical, food and other customers with improved safety and quality assurance through visibility into the status of loads during transportation. The move combines Coretex’s sensor-based reefer technology and cloud-based software platform with SkyBitz’s trailer tracking technology for both powered and non-powered asset tracking.
TurboFil introduces module for automated syringe filling and assembly
TurboFil Packaging Machines LLC, a company specializing in design and development of liquid filling and assembly machines, has introduced a module offering automated, simplified production for a range of syringe formats. TurboFil’s SimpliFil Syringe Filling & Assembly System Employing a setup that fills syringes via ceramic piston, peristaltic pump or direct draw from a reservoir bag, the company’s SimpliFil Syringe Filling & Assembly System is suitable for small to medium batches.
UNICEF to stockpile more than a half billion syringes by year end
In anticipation of forthcoming Covid-19 vaccine approvals, the United Nations Children’s Fund (UNICEF) announced plans to stockpile 520 million syringes in its warehouses, part of a larger plan to have a billion syringes ready for use through 2021 in order to guarantee initial supply and help ensure that syringes arrive before vaccines are distributed.
UK importers/exporters warned to take immediate action as Brexit nears
Many businesses trading abroad ‘are in the dark’ about what they should be doing to prepare financially for the Brexit January 1, 2021 deadline, according to feedback received by Hamilton Court FX, a UK-based consulting firm that provides foreign exchange (FX) transactional advice and delivery.
DataLase launches functional masterbatch additive for plastics integration
DataLase, a photonic printing specialist, has developed a masterbatch additive suitable for a range of plastics for pharmaceutical, medical and other industries. The additive addresses challenges faced by production and manufacturing companies with product coding applications, such as printing expiration dates and lot numbers.
Medical Knowledge Group acquires life sciences market research firm
Medical Knowledge Group, LLC, a marketing and technology-oriented service for companies in the biopharmaceutical industry, has acquired research and consulting firm Magnolia Innovation. Founded in 2013, Magnolia focuses exclusively on life sciences to help build, launch and redefine biopharmaceutical brands by leveraging market insights and business strategies. The firm is based in Hoboken, NJ.
Drone deliveries of cold chain medicines begin in rural North Carolina
Volansi, Inc., an on-demand aerial delivery service for time-critical shipments, has begun delivering cold chain medicines from Merck’s Wilson, N.C. manufacturing site to Vidant Healthplex-Wilson, a medical center operated by Vidant Health and serving rural portions of the state. Initial flights in the project resulted in the first drone delivery of temperature-controlled medicines within the U.S., according to Volansi.
Etihad Cargo to utilize latest CSafe high-performing containers for flights
Etihad Cargo has approved the use of CSafe Global’s high-performing container, the CSafe RAP, across its global fleet of wide-body and freighter aircraft. CSafe Global provides end-to-end thermal shipping for the pharmaceutical and life science industries with a presence in more than 150 countries.
BioLife division gets $2.7m cold chain and storage contract for Covid-19 vaccines
BioLife Solutions, Inc.’s recently acquired SciSafe division has been awarded a two-year contract estimated at $2.7 million from an unnamed ‘large pharmaceutical company’ for cold chain management and storage of Covid-19 vaccines. SciSafe, a provider of biological materials storage founded in 2010, maintains four cGMP-compliant facilities located in New Jersey, Massachusetts and Utah, with an expansion plan focused on the cell and gene therapy clusters located around the world.
Covectra introduces suite of services for comprehensive serialization and traceability
Covectra has launched a suite of serialization and track & trace engineering, integration and consulting options to complement its products and services, allowing businesses to address supply chain challenges, optimize technology products and implement new processes quickly and cost effectively.
IntegriChain launches advanced analytics to improve forecasting and accrual processes
IntegriChain, a Philadelphia-based data and managed services company, has introduced GTN Analytics, a service for life sciences manufacturers to improve visibility to the market access datasets that power the accuracy of accruals and forecasting processes, delivers best practices reports and metrics, and offers visualizations of gross-to-net, or GTN, trends.
Air transport groups find ‘a concerning lack of readiness’ for Covid-19 vaccine logistics
The International Air Cargo Association (TIACA) and Pharma.Aero, a cross-industry consortium focused on reliable end-to-end air transportation for pharmaceutical shippers, this week sounded an alarm over the current state of air cargo readiness for upcoming Covid-19 vaccine transportation.
Momentive Technologies and Stevanato Group collaborate on vials packaging
Momentive Technologies and Stevanato Group agreed to supply Momentive’s Pur Q fused quartz vials in Stevanato’s EZ-fill packaging format. The Pur Q vials are ultra-high-purity fused quartz vials available for pharmaceutical packaging. The EZ-fill secondary packaging provides a fully integrated, ready-to-use option for aseptic fill-finish operations. Pur Q fused quartz vials.
Authentix acquires Bibliotheca anticounterfeiting unit
Authentix, Inc., an authentication and information service based in Addison, TX, has acquired the Traceless Authentication Group from Bibliotheca, Inc. a library systems company serving libraries worldwide. Rochester, NY–based Traceless delivers anticounterfeiting and diversion control options to customers in the global pharmaceuticals, spirits, and apparel industries.
Balaxi Ventures renamed to better reflect its core focus on pharma
India’s Ministry of Corporate Affairs has granted formal approval to Balaxi Ventures Ltd to change the company’s name to Balaxi Pharmaceuticals Ltd. The move received shareholder okay last month at the company’s annual general meeting. Hyderabad, India-based Balaxi supplies “frontier” markets in Angola, Guatemala and the Dominican Republic with branded, generic and over-the-counter medicines that address multiple therapeutic segments.
IQVIA: Biosimilars on track to reduce drug costs by $100b over next five years
Biosimilar medicine availability and use are growing and on track to reduce drug costs by $100 billion over the next five years, according to a new report from the IQVIA Institute for Human Data Science. The development and approvals of biosimilars have been accelerating in the U.S. over the past two years, bringing a total of 33 approvals across 13 molecules through the 2020 second quarter. Only 22 of these have launched thus far due to legal challenges and commercial agreements.
Abzena invests $60 million to expand cGMP manufacturing capacity
Abzena, a contract provider of integrated services for biologics and bioconjugates, has invested $60 million into a new facility for late phase and commercial current good manufacturing practice (cGMP) production. The new 50,000 square foot ‘Lusk’ facility at the company’s site in San Diego houses a process development laboratory and two new cGMP manufacturing cleanrooms for 500L and 2,000L scale in Sartorius single use bioreactors.
Show More
loading
Actions
Get in touch with Andy
Contact Andy, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack